This study focuses on patients with Non-small Cell Lung Cancer (NSCLC) who have had their cancer surgically removed. The study compares two medications: QL2107, which is being tested as a potential biosimilar medication, and Keytruda (also known as pembrolizumab). A biosimilar is a medication that is very similar to an already approved biological medicine. The purpose is to determine if QL2107 works in the same way as Keytruda in the body.

The treatment involves receiving either QL2107 or Keytruda through intravenous infusion (given directly into a vein). The medication is given every three weeks for up to 12 months. Both medications are given at a dose of up to 200 milligrams per infusion. Patients who participate in the study will have had their cancer completely removed through surgery and will have already completed chemotherapy treatment before starting this medication.

Throughout the study, doctors will take blood samples to measure how the medication moves through the body. These measurements will help determine if QL2107 and Keytruda behave similarly in patients’ bodies. The study is “double-blind,” which means neither the patients nor the doctors know which medication each patient is receiving during the study.